Sobrera Pharma AB is pleased to announce the Decisions to Grant on the European patent 3582764 titled ’Treatment of Alcohol Use’ by the European Patent Office (EPO). The decision to grant on the [...]
Recruitment of patients to the phase II study (COMB study) is ongoing at the clinical study site in Gothenburg and in Stockholm. The study team is sharing information about the study including [...]
Sobrera Pharma AB announces 28 MSEK capital raise through a directed share issue to finance the continued development of SO-001, a new oral therapy for patients with Alcohol Use Disorder (AUD). [...]
Swedish life science company, Sobrera Pharma, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development and [...]
Combined administration of varenicline and bupropion produces additive effects on accumbal dopamine and abolishes the alcohol deprivation effect in rats Bo Söderpalm | Klara Danielsson | Andrea [...]
